Citius Pharmaceuticals (CTXR) to Announce Earnings on Tuesday

Citius Pharmaceuticals (NASDAQ:CTXR) will likely be announcing its Q3 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.36) per share and revenue of $5.4590 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). On average, analysts expect Citius Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Citius Pharmaceuticals Stock Performance

CTXR traded up $0.02 during midday trading on Tuesday, hitting $0.62. The company had a trading volume of 67,671 shares, compared to its average volume of 565,418. Citius Pharmaceuticals has a twelve month low of $0.47 and a twelve month high of $2.19. The company has a market capitalization of $16.96 million, a PE ratio of -0.29 and a beta of 1.03. The firm’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.70.

Analyst Ratings Changes

Several research firms have recently commented on CTXR. Wall Street Zen cut shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Zacks Research raised Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Citius Pharmaceuticals has a consensus rating of “Hold” and an average price target of $5.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of Citius Pharmaceuticals during the second quarter worth $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the second quarter valued at about $40,000. Asset Advisory Group Inc. bought a new position in Citius Pharmaceuticals during the fourth quarter worth about $46,000. Finally, Heights Capital Management Inc. bought a new position in Citius Pharmaceuticals during the fourth quarter worth about $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.